These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 36862965)
1. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future. Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965 [TBL] [Abstract][Full Text] [Related]
2. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Tan E; Sahin IH Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189 [No Abstract] [Full Text] [Related]
3. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm. Ozer M; Vegivinti CTR; Syed M; Ferrell ME; Gonzalez Gomez C; Cheng S; Holder-Murray J; Bruno T; Saeed A; Sahin IH Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568648 [TBL] [Abstract][Full Text] [Related]
5. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer. Veen T; Kanani A; Lea D; Søreide K Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222 [TBL] [Abstract][Full Text] [Related]
9. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers. Liu YL; Weigelt B Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y Front Immunol; 2022; 13():795972. PubMed ID: 35371084 [TBL] [Abstract][Full Text] [Related]
15. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A; Berlin J; Bekaii-Saab T; Lesinski GB; El-Rayes BF; Wu C Oncologist; 2021 Aug; 26(8):668-675. PubMed ID: 33631043 [TBL] [Abstract][Full Text] [Related]
16. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
17. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
18. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer. Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]